FORMULATION AND DEVELOPMENT OF METOPROLOL SUCCINATE TABLETS IN TERMS OF FLOATING DRUG DELIVERY SYSTEM

The main goal of this study is to formulate and develop Metoprolol Succinate Floating tablet. To optimize Metoprolol Succinate floating tablet and carry out stability studies as per ICH guidelines. Metoprolol Succinate is classified as a BCS Class I medication, commonly prescribed for managing conditions like hypertension, angina pectoris, and heart attacks. It has a relatively short half-life, ranging from 3 to 7 hours, and its absorption can vary because of its poor solubility. Floating tablets of Metoprolol Succinate were formulated using hydrophilic polymers such as Hydroxypropyl Methylcellulose (HPMC), Carbopol, and swelling agents like calcium carbonate to create a buoyant matrix. Various formulations were developed by altering polymer content. Tablets were evaluated for parameters including hardness, thickness, weight variation, friability, drug content, floating lag time, total floating duration, swelling index, and in vitro drug release profile. The FTIR data indicates that there are no interactions of excipients with the drug. Among the formulations tested, formulation F5 exhibited the most beneficial qualities. It demonstrated a consistent drug release of 92.63% and maintained buoyancy for up to 16 hours. All key evaluation parameters such as floating lag time, swelling index, and in vitro drug release were optimized in F5 compared to other formulations. The stability study indicates that there are no significant differences in the physical parameters. The results indicate that a sustained-release floating drug delivery system for Metoprolol Succinate was successfully developed. The optimized formulation (F5) significantly improves gastric retention and drug release, making it a promising candidate for enhanced antihypertensive therapy.